To date, according to the EULAR recommendations [62], if axial disease predominates and presents insufficient response to non-steroidal anti-inflammatory drugs, treatment with TNF inhibitor or IL-17A inhibitor should be considered. The gene discussed is IL17A; the disease is glycogen storage disease VI.